NextCure (NASDAQ:NXTC) Stock Price Down 3.7% – What’s Next?

NextCure, Inc. (NASDAQ:NXTC)’s share price was down 3.7% on Monday . The stock traded as low as $12.16 and last traded at $13.22. Approximately 88,662 shares changed hands during mid-day trading, an increase of 181% from the average daily volume of 31,518 shares. The stock had previously closed at $13.73.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. LADENBURG THALM/SH SH raised NextCure from a “neutral” rating to a “buy” rating and set a $18.00 price objective for the company in a research note on Friday, November 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NextCure in a report on Wednesday, January 28th. Finally, Wall Street Zen raised NextCure to a “hold” rating in a report on Saturday, December 13th. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $23.00.

NextCure Stock Performance

The firm has a 50-day moving average of $12.55 and a 200-day moving average of $9.64. The firm has a market capitalization of $46.40 million, a P/E ratio of -0.55 and a beta of 1.54.

Institutional Investors Weigh In On NextCure

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NXTC. Marshall Wace LLP purchased a new stake in shares of NextCure in the 4th quarter worth about $160,000. Millennium Management LLC bought a new stake in shares of NextCure during the fourth quarter valued at approximately $185,000. Geode Capital Management LLC grew its stake in NextCure by 18.6% in the fourth quarter. Geode Capital Management LLC now owns 23,157 shares of the company’s stock worth $329,000 after purchasing an additional 3,636 shares during the period. Renaissance Technologies LLC raised its holdings in NextCure by 18.7% in the fourth quarter. Renaissance Technologies LLC now owns 33,634 shares of the company’s stock worth $477,000 after purchasing an additional 5,300 shares in the last quarter. Finally, Boothbay Fund Management LLC bought a new position in NextCure in the fourth quarter worth $988,000. 42.65% of the stock is currently owned by institutional investors.

NextCure Company Profile

NextCure, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.